MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Cash Conversion Cycle 2011-2026 | PKI
Annual Cash Conversion Cycle PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92.2 | 87.6 | 92.9 | 91.3 | 250 | - | 121 | 113 | 99.6 | 110 | - | 110 | 108 | 101 | 94.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 | 87.6 | 113 |
Quarterly Cash Conversion Cycle PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 146 | 139 | 149 | - | 149 | 146 | 156 | - | 155 | 132 | 127 | - | 153 | 170 | 157 | 71.6 | 172 | 105 | 50.8 | - | 118 | 123 | 133 | 83.3 | 124 | 121 | 127 | 76.3 | 117 | 112 | 116 | 78.5 | 132 | 133 | 127 | 68.7 | 127 | 122 | 66.8 | - | 112 | 107 | 115 | 70.6 | 113 | 110 | 112 | 72 | 111 | 108 | 112 | 72.8 | 108 | 105 | 93 | 69.5 | 102 | 94.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 172 | 50.8 | 115 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
111 | $ 115.55 | 3.81 % | $ 35.1 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 20.81 | 0.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
-2.46 K | $ 1.55 | 1.31 % | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 24.49 | 1.03 % | $ 680 M | USA |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 15.19 | 2.64 % | $ 459 M | USA |
 |
Aspira Women's Health
AWH
|
1.01 K | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 118.33 | 1.86 % | $ 9.76 B |  Irlanda |
 |
Illumina
ILMN
|
142 | $ 126.74 | 5.29 % | $ 20.2 B | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
65 | $ 166.97 | 1.91 % | $ 8.28 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 84.62 | 4.25 % | $ 5.71 B | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 418.66 | 1.23 % | $ 12.1 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 87.08 | 4.4 % | $ 10.9 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
Koninklijke Philips N.V.
PHG
|
89 | $ 26.34 | 2.95 % | $ 20 B |  Niderland |
 |
Myriad Genetics
MYGN
|
49.3 | $ 4.75 | 1.5 % | $ 440 M | USA |
 |
Interpace Biosciences
IDXG
|
62.9 | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 9.26 | 3.35 % | $ 1.19 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
172 | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 256.8 | -0.13 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 16.46 | -0.48 % | $ 368 M | USA |
 |
Natera
NTRA
|
81.5 | $ 206.16 | 5.86 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
150 | $ 9.4 | 4.33 % | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 194.2 | 2.58 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
-82.8 K | - | -2.3 % | $ 19.4 M | USA |
 |
Exagen
XGN
|
-3.23 | $ 2.9 | 5.07 % | $ 62.5 M | USA |
 |
Precipio
PRPO
|
19.9 | $ 30.9 | 3.21 % | $ 49.6 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
149 | $ 17.0 | 4.68 % | $ 179 M | China |
 |
Personalis
PSNL
|
-11.5 | $ 5.52 | 9.52 % | $ 327 M | USA |